Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A second phase III trial of arhalofenate in combination with febuxostat in patients with chronic gout

Next Previous
Trial Profile

A second phase III trial of arhalofenate in combination with febuxostat in patients with chronic gout

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arhalofenate (Primary) ; Febuxostat
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Sponsors CymaBay Therapeutics

Most Recent Events

  • 09 Aug 2016 According to a CymaBay Therapeutics media release, the company has completed End-of-Phase 2 discussions with the FDA and reached agreement on all of the key elements of the planned Phase 3 program.
  • 22 Jan 2016 New trial record
  • 20 Jan 2016 According to a CymaBay Therapeutics media release, this is one of the 3 phase III trials that will support registration.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top